CONTEXT: A very brief update, but a potentially very important one. The FDA is convening the paediatric subcommittee to discuss how to effectively use PROs in oncology studies. We will Continue Reading
CONTEXT: Commercial announcement of a RWE tie-up between C-Path Institute and Tufts. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 5 1. “”This will significantly add Continue Reading
CONTEXT: Real-world study from Japan showing increased rates of pneumonitis with first-line pembrolizumab plus chemotherapy in patients with advanced NSCLC. IMPACT: Medium READ TIME: 2 mins Quality Level Mean [1 Continue Reading
CONTEXT: Another commercial announcement of a tie up on RWD sources | US only. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 3 1. “Through the Continue Reading
CONTEXT: A proper peer reviewed study article on a retrospective study based on an oncology registry in Canada highlighting the differences in outcomes for rural versus urban patients. READ TIME: Continue Reading
CONTEXT: Commercial merger announcement. Advise caution with regards to applicability in RWR as the technology platform is heavily clinical research focused. IMPACT: Low READ TIME: 1 min *1. “MUNICH–(BUSINESS WIRE)–XClinical, Continue Reading
CONTEXT: Mostly advert for cox platform, but interesting EMR based use of RWD – stretching the definition of a decentralised study though, US Only IMPACT: RWE insights based on de-identified Continue Reading
CONTEXT: Oncology news article on use of RWR in oncology. Nothing new in terms of data use, more confirmation of RWD in oncology research. However, an interesting perspective from the Continue Reading
IMPACT: Preliminary RWE on effectiveness of single dose of Pfizer vaccine; 1st dose of the Pfizer vaccine seen to curb infection rates by 50% within 14 days; data from 800,000 Continue Reading
COMMENTS: Good story on use of RWE / RWR in oncology. READ TIME: 2 mins *1. “Sir Mick Peake, clinical director for the Centre for Cancer Outcomes within UCLH’s Cancer Continue Reading
